Torrent Pharmaceuticals gets rights to generic of Pfizer’s oral Covid-19 treatment

Torrent Pharmaceuticals has entered into a licensing agreement with Medicine Patent Pool (MPP) for manufacturing and commercializing the generic version of Pfizer’s oral Covid-19 treatment.

Pfizer’s oral Covid-19 treatment is made up of PAXLOVID (nirmatrelvir), which inhibits a SARS-CoV-2 protein to prevent the SARSCoV-2 virus from replicating and ritonavir, which slows down the breakdown of nirmatrelvir to help it stay in the body for a longer duration at higher concentrations.

The licensing agreement with Medicine Patent Pool is aimed at increasing wider access to Covid-19 treatment in 95 low‐ and middle-income countries, including India.

Torrent Pharmaceuticals gets rights to the generic version of Pfizer’s oral Covid-19 treatment

Torrent Pharmaceuticals gets rights to the generic version of Pfizer’s oral Covid-19 treatment. Image courtesy of Pete Linforth from Pixabay.

Previously, Medicine Patent Pool had signed a licensing deal with PF Prism Holdings, a subsidiary of Pfizer, to get the rights to sub-license manufacture and commercialization rights to sub-licensees.

Torrent Pharmaceuticals will launch the oral Covid-19 treatment after securing the required approval from regulatory agencies.

Aman Mehta — Executive Director of Torrent Pharmaceuticals said: “We are pleased to enter into this agreement with MPP and is part of our continued endeavor to make Covid treatments as accessible as possible to patients.”

Related Posts

CATEGORIES
TAGS
Share This